Immunovia AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 0.156 million compared to SEK 0.52 million a year ago. Revenue was SEK 0.604 million compared to SEK 0.598 million a year ago.

Net loss was SEK 2.95 million compared to SEK 51.66 million a year ago. Basic loss per share from continuing operations was SEK 0.07 compared to SEK 2.28 a year ago. Diluted loss per share from continuing operations was SEK 0.07 compared to SEK 2.28 a year ago.